Can starting multiple kidney drugs at once slow Diabetes-Related kidney damage?
NCT ID NCT07547878
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether starting four approved kidney disease medicines quickly (over about 8 weeks) is safe and effective for people with type 2 diabetes and chronic kidney disease. Researchers will compare this rapid approach to usual care, where medicines are started one at a time. The study involves 64 participants and will track kidney function, protein in urine, and how many people can stay on all four medicines for 6 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Finerenone, Semaglutide, and ACE inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril)
- What this could lead to
- If this approach works, it could show that starting multiple kidney-protecting medicines at once is safe and helps slow kidney damage in people with diabetes.
- What could go wrong
- This is a small pilot study with only 64 people, so results may not apply to everyone. Starting several medicines quickly could increase side effects like high potassium or low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 84 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 18-84 years * eGFR 45 to ≤90 mL/min/1.73 m2 * UACR \>200 mg/g * diagnosis of T2D * receiving ≤2 guideline-recommended drug classes irrespective of dose for ≥4 weeks prior to screening * eligible for all 4 drugs * systolic BP (SBP) \>90 mmHg * those willing to provide written informed consent and to adhere to study visits. Exclusion Criteria: * Type 1 diabetes * any known primary non-diabetic kidney disease (i.e., polycystic kidney disease, glomerulonephritis, interstitial nephritis, etc.) * history of kidney transplant * liver disease (i.e., aspartate transaminase or alanine transaminase \>5 times, or bilirubin \>3 times the upper limit of normal) * serum potassium \>5.5 mEq/L at baseline * known hypersensitivity to any study drug * life expectancy \<6 months * active malignancy or infection * brittle diabetes (defined as severe glycemic instability with hospitalization or emergency care for hypoglycemia or hyperglycemia within the past 6 months) * high-risk of hypoglycemia (Clarke or Gold score ≥4) * predicted 12-month risk of hypoglycemia related emergency visits or hospitalizations \>5% using the Kaiser Permanente hypoglycemia prediction score * high dose insulin use (\>1 unit/kg/day). * RASi: hyperkalemia or angioedema * SGLT2i: diabetic ketoacidosis, type 1 diabetes, recurrent genitourinary infections * ns-MRA: hyperkalemia * GLP1-RA: personal or family history of medullary thyroid carcinoma, known gastroparesis, or pancreatitis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Baylor Scott and White Medical Center- Temple
Temple, Texas, 76508, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Can mindfulness and yoga rewire diabetes habits?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a breathing workout and walks help dialysis patients with irregular heartbeats?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?